Skip to main content
TipRanks
Go Ultimate75% OFF

Biomea Fusion (BMEA) Stock Price & Analysis

1,215 Followers

BMEA Stock Chart & Stats

$0.57-$0.01(-2.38%)
At close: 4:00 PM EST
$0.5$1$1.5$2Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$0.54 - $0.60
52-Week Range
$0.45 - $2.24
Previous Close
$0.59
Volume
N/A
Average Volume (3M)
2.10M
Market Cap
$42.76M
Enterprise Value
$70.28M
Total Cash (Recent Filing)
$26.40M
Total Debt (Recent Filing)
$506.00K
Price to Earnings (P/E)
―
Beta
2.02
Next Earnings
Mar 30, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

BMF-650 Phase 1 Progress

The Phase 1 readout advances BMF-650 into human clinical development and supports continued assessment of its oral GLP-1 approach. Its stated focus on tolerability, one-step titration and bioavailability could provide durable product differentiation if later trials confirm these benefits.

Improving Loss Trend

The substantial reduction in reported net losses indicates meaningful cost containment or lower operating spend over successive periods. Although the company remains unprofitable, a lower expense base can extend development resources and improve financial flexibility while clinical programs advance.

Low Financial Leverage

Low leverage limits fixed debt obligations and reduces the balance sheet's exposure to interest and refinancing pressure. This gives management more flexibility to direct available capital toward clinical development, although it does not remove the need for future funding.

Bears Say

Pre-Revenue Business Model

The absence of product revenue means Biomea currently lacks commercial operating leverage and must fund research and development before establishing a recurring revenue base. This leaves future financial performance highly dependent on clinical progress and eventual product commercialization.

Persistent Cash Burn

Ongoing negative operating and free cash flow indicates that the business is not yet self-funding its development activities. Continued reliance on external capital can constrain strategic flexibility and create durable financing risk until a product generates meaningful cash receipts.

Eroding Equity Base

The sharp decline in shareholders' equity shows that accumulated losses have materially reduced the capital base. A thinner equity cushion leaves less room to absorb setbacks and may increase dependence on future financing to sustain clinical programs and operating commitments.

Biomea Fusion News

BMEA FAQ

What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $0.45 and its highest was $2.24 in the past 12 months.
What is Biomea Fusion’s market cap?
Biomea Fusion’s market cap is $42.76M.
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s next earnings report is estimated for Mar 30, 2027 (not yet confirmed), which is in 129 days.
How were Biomea Fusion’s earnings last quarter?
Biomea Fusion released its earnings results on Nov 10, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.207 by $0.117.
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate is -0.21.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 72,678,080 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Biomea Fusion reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.207. Following the earnings report the stock price went up 11.517%.
Which hedge fund is a major shareholder of Biomea Fusion?
Hedge funds hold Biomea Fusion shares: the largest hedge-fund position in Biomea Fusion is 72,278,932 shares, and hedge funds increased their holdings by 127.5K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology